Juicebox avatar

Dexa/Juicebox

Learn more
Published Jun 28, 2021

#498 Dexcom G7 Talk With Dexcom CEO Kevin Sayer

Kevin Sayer, CEO of Dexcom, delves into the technological and strategic innovations of the Dexcom G7, including its integration with insulin pumps, partnerships with tech giants, and transition to pharmacy distribution, all designed to enhance diabetes management and accessibility.
Episode Highlights
Juicebox Podcast: Type 1 Diabetes logo

Topics covered

Popular Clips

Questions from this episode

Episode Highlights

  • Pump Integration

    The integration of Dexcom's G6 and G7 with insulin pumps is a key focus for the company. explains that while the G7 offers improvements like a smaller device and factory calibration, it still allows user calibration for flexibility 1. He notes that integration with Omnipod and Tandem pumps is underway, with some delays expected due to the complexity of the process 2.

    It's different. I haven't experienced that much. And in all answers, Scott, this is one place where you have to go out in the field and have the product work. You have to see how it works with individual phones, individual users.

    ---

    Sayer emphasizes the importance of making the technology user-friendly and adaptable to individual needs.

       

    Tech Collaborations

    Dexcom's collaboration with companies like Apple aims to enhance user experience with the G7. mentions that while direct integration with the Apple Watch is not available initially, the hardware is capable, and future updates will address this 3. He highlights the need to ensure that users are aware of the limitations, such as the lack of alerts when the watch is charging 3.

    The nice part about it is it has the hardware chops, the bluetooth configuration, and all the capability to go direct to Apple watch to get the app done.

    ---

    Sayer is optimistic about the progress and anticipates sharing more updates after the upcoming earnings call 4.

Related Episodes